

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**PuraPharm**

**PURAPHARM CORPORATION LIMITED**

**培力控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1498)**

## **CLARIFICATION ANNOUNCEMENT AND BUSINESS UPDATE**

This announcement is made by PuraPharm Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Since the outbreak of the new coronavirus pneumonia epidemic (the “**Epidemic**”) in the People’s Republic of China (the “**PRC**”), a number of provinces and cities in the PRC have taken emergency public health measures and various actions to prevent the spread of the Epidemic. The government of the PRC issued notices which extend the period of Chinese new year holiday in the PRC.

The board of directors (the “**Board**”) of the Company noted there are rumours that the operation of the Concentrated Chinese Medicine Granule (“**CCMG**”) production facilities in Nanning, Guangxi, PRC (the “**Nanning Production Facilities**”) have been disrupted and suspended due to the spread of the Epidemic. The Company hereby clarifies that the aforementioned rumours are not true. The Nanning Production Facilities have resumed its production as usual on 3 February 2020.

The Board would also like to inform shareholders and potential investors that due to the spread of the Epidemic and the expected increase in demand for healthcare products, the Group plans to increase the production and supply of its Chinese healthcare products, especially Immuzac®, which is jointly researched and developed with The University of Hong Kong. Immuzac® is a Yunzhi & Lingzhi-derived standardized natural health product, and researches showed that its ingredient is effective in strengthening human immune functions in defense against infection, thereby increasing human resistance to illnesses.

**Shareholders of the Company and potential investors are advised not to unduly rely on the information contained in this announcement and to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**PuraPharm Corporation Limited**  
**Chan Yu Ling, Abraham**  
*Chairman*

Hong Kong, 11 February 2020

*As at the date of this announcement, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Mr. Chan Kin Man, Eddie, and Ms. Man Yee Wai, Viola; non-executive director of the Company is Mr. Chow, Stanley; and the independent non-executive directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.*